Objective: The ileal brake is a feedback mechanism activated by nutrients, especially fat, with marked effects on satiety. The effects of low doses of ileal fat on satiety are largely unknown. We therefore studied the effect of ileal vs oral delivery of low doses of fat on satiety and gut peptide secretion. Design: Randomized, single-blind crossover design. Subjects: Sixteen healthy, normal-weight volunteers (6 male; mean age 26 years, mean body mass index 22.4). Intervention: Participants were intubated with a 290-cm-long nasoileal tube and consumed, on 3 consecutive days, either a liquid breakfast with 3 g fat followed by an ileal placebo infusion at t ¼ 105-150 min (treatment C) or a fat-free liquid breakfast followed by an ileal infusion of either an emulsion of 3 g (treatment I3g) or 9 g (treatment I9g) fat (safflower oil). Measurements: Satiety parameters by visual analog scales and plasma concentrations of CCK and PYY. Results: C significantly increased satiety and CCK secretion compared with the fat-free breakfast. Ileal fat perfusion of both 3 and 9 g (I3g and I9g) significantly increased satiety during and after fat perfusion, without differences in satiety between I3g and I9g. During ileal fat infusion, CCK increased dose dependently, whereas PYY concentrations increased significantly only after 9 g of fat. Secretion of CCK but not of PYY correlated to satiety levels. Conclusion: Postprandial satiety following a liquid breakfast can be effectively and significantly increased by small amounts (as little as 3 g) of fat perfused into the ileum. Ileal fat dose-dependently increased CCK but not PYY secretion. The satiating effect of ileal fat may be partly mediated by CCK.
Introduction
Satiety feelings on a meal-to-meal basis are to a large extent determined by gastrointestinal signals. 1 An option to prolong satiety and to reduce food intake is by delaying gastric emptying and/or small intestinal transit time. [2] [3] [4] This may be achieved by activation of the ileal brake. 5 The ileal brake is the primary inhibitory distal-to-proximal feedback mechanism that controls meal transit through the gastrointestinal tract and is thought to regulate and optimize nutrient digestion and absorption. 5 Several studies have shown that direct delivery of lipids into the ileum delays gastric emptying, 6 prolongs small intestinal transit time 7 and induces satiety. 8 Long-chain fatty acids are potent triggers of the ileal brake, 5, 7 and several studies have demonstrated that the ileal brake is already activated by small amounts of fat or free fatty acids. [9] [10] [11] However, it is not known whether these small amounts of fat are able to induce satiety and influence food intake. Evidence for a direct effect of the ileal brake on satiety and food intake in humans is limited to two publications from the same research group. 8, 12 An ileal infusion of 370 kcal of lipids resulted in a significant reduction in hunger with a net decrease in caloric intake of 711 kcal. It should be noted that the amounts of fat used in these studies were high (41 g), and no studies have been performed on the satiating effect of ileal brake activation by very small amounts of fat. Our aim was to explore whether delivery of small amounts of lipids into the ileum will further increase postprandial satiety and whether this effect is dose dependent. A second aim was to evaluate the effect of ileal lipid administration on gut peptide secretion, more specifically on cholecystokinin (CCK), as a more proximal gut peptide with well-known satiety effects, 13 and peptide YY, as a distal gut peptide and proposed biomarker for the activation of the ileal brake. 10 We constructed the following hypotheses: compared with oral ingestion of 3 g of lipid added to a liquid meal, delivery of the same amount of lipid through postprandial (after ingestion of the fat-free breakfast) perfusion into the ileum will (1) lead to an increase in postprandial satiety, (2) be dose dependent (9 g vs 3 g in the ileum) and (3) lead to distal gut hormone secretion.
Methods
Participants Healthy volunteers were recruited by public advertisement. Sixteen volunteers were seen for screening. This included a questionnaire (Dutch Eating Behavior Questionnaire) to exclude restrained eaters, blood tests and physical examination. Signed informed consent was obtained from each individual. None had a history of gastrointestinal disease or abdominal surgery, and none were using any medication. After providing their written informed consent, 16 healthy individuals (mean age 26 years, range, 18-60 years, mean body mass index 22.4 kg/m 2 , range 18.7-28.6 kg/m 2 ) participated in this study.
Nasoileal catheter
Participants were intubated with a 9-lumen 290 cm nasoileal catheter (eight infusion ports, one balloon inflation channel, Dentsleeve International Ltd, Mississauga, Canada). Through an anaesthetized nostril, the catheter was introduced into the stomach and allowed to pass through the pylorus to the ileum by peristalsis. After passing the ligament of Treitz, a small balloon at the tip was inflated to facilitate passage of the catheter to the ileum. The tip was placed in the ileum (at least 120 cm catheter length distal from the pylorusFthe catheters were fitted with radiopaque markers that enabled assessment of the length of catheter), so that three infusion ports were available in the ileum, and at least one infusion port in the duodenum. After this, the participants were instructed to inflate and deflate the balloon during the evening, and inflate the balloon upon waking up, to advance further passage of the tube. During the positioning and before and directly after every test day, the position of the catheter was checked fluoroscopically. The fluoroscopy techniques used do not enable assessment of the position of the tube compared with the ileocecal valve. However, on fluoroscopy, it was shown that the catheter made multiple loops within the small intestine. Furthermore, in two cases, contrast fluid was used to visualize the exact position of the catheter. After infusion of the contrast fluid, the contrast appeared in the colon within a few minutes, and a short segment of small bowel was visible (30-60 cm).
Experimental design
In this single-blind, randomized controlled crossover design, each participant participated in three experiments on three consecutive days in random order. In treatment C (oral fat, 3 g), participants received a liquid meal with 3 g of fat (breakfast X, BX) and an ileal placebo infusion (emulsion A). In treatment I3g (ileal fat, 3 g), participants received a fat-free liquid meal (breakfast Y, BY) and an ileal infusion with an emulsion with 3 g of fat (emulsion B). In treatment I9g (ileal fat, 9 g), participants received fat-free breakfast (BY) and an ileal infusion with an emulsion with 9 g of fat (emulsion C).
On each study day (Figure 1 ), the participant arrived at the laboratory at 0800 hours following an overnight fast. After checking the correct position of the catheter by fluoroscopy, a venous catheter was placed in a forearm vein for collection of blood samples. At 0900 hours, a basal blood sample and a basal visual analog scale (VAS) score were taken. Immediately thereafter, the liquid meal was consumed. The ileal infusion was scheduled from t ¼ 105-150 min after meal ingestion, at a rate of 1 ml min
À1
. This resulted in an infusion rate of 0.6 kcal min À1 for the I3g treatment and 1.35 kcal min À1 for the I9g treatment. For this experiment, the follow-up ended at t ¼ 240 min. This study was designed as a proof-of-principle study to evaluate dose-dependent effects of the ileal brake on satiety. The timing of the ileal fat perfusions is crucial and should represent the physiological postprandial conditions. We chose the infusion period at t ¼ 105-150 min, as we thought this would best represent the physiological moment of arrival of the bulk of the fat.
14 Furthermore, Goebell et al.
15
demonstrated that delivery of a meal marker to the ileum was the highest at 2-2.75 h after ingestion of the meal. In this study, we tried to resemble physiologic postprandial situation. randomized. Each test day started with consumption of breakfast. Each participant consumed either a breakfast with 3 g fat followed by an ileal saline infusion at t ¼ 105-150 min (treatment C) or a fat-free breakfast followed at t ¼ 105 min by an ileal infusion of either an emulsion of 3 g (treatment I3g) or 9 g (treatment I9g) safflower oil. *Denotes drawing blood sample and satiety questionnaire.
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Liquid meals and emulsions
The liquid breakfasts and the fat emulsions ( þ placebo) for ileal perfusion were produced by Unilever Research and Development, Vlaardingen, the Netherlands. Two 325-ml breakfast drinks were produced: BX (220 kcal) consisting of 99.1% Slim.Fast French Vanilla US (fat-free) and 0.9% safflower oil, and BY (193 kcal) consisting of 100% Slim.Fast French Vanilla US (fat-free). Three emulsions were produced: placebo (named emulsion AFstrictly speaking, this is not an emulsion as it does not contain any oil) consisted of 1.0% sodium caseinate, 0.1% skim milk powder, 0.1% Guar gum, 0.9% sodium chloride in demineralized water. Oil emulsion B was composed of 1.0% sodium caseinate, 0.1% skim milk powder, 0.1% Guar gum, 0.9% sodium chloride and 6.0% safflower oil in demineralized water. Oil emulsion C was identical to emulsion B except that the oil concentration was 18% and NaCl was 0.66%.
Satiety scores
The volunteers rated their feelings of hunger and satiety (and appetite for a meal, fullness, appetite for a snack and satiety) by means of a mark on 64-mm line scales using an electronic visual analog scale (EVAS), iPAQ. 16 This scale was anchored at the low end with the most negative or lowest intensity feelings (for example, 'extremely unpleasant', 'not at all'), and with opposing terms at the high end (for example, 'extremely pleasant', 'very high', 'extreme') as described by Flint et al.
17
Measurements were taken during the test day every 30 min from t ¼ 0-240 min, and every 15 min during infusion of emulsion (t ¼ 105-150 min).
Gastrointestinal disturbances were scored using forms (4-point scale: 'none', 'a little', 'some', 'substantial') at regular intervals (t ¼ À5, 105, 150, 235 min). The following gastrointestinal symptoms were scored: nausea, heartburn, belching, abdominal bloating, abdominal pain, borborygmi, flatulence and urge to defecate. The following general symptoms were also scored: headache, malaise, dizziness and fatigue.
Hormone assays Blood samples were drawn at t ¼ 0 (start meal ingestion),
Total plasma peptide YY (PYY) was measured by radioimmunoassay. PYY antiserum was generated in rabbits by intracutaneous injections of synthetic human PYY (BACHEM Biochemica GmbH, Switzerland). PYY was labeled with 125 Iodine with chloramine T. The assay is highly specific. There is no cross-reactivity with PP or VIP. The detection limit is 10 pmol l
À1
. Both PYY and PYY bind to the antibody in dilutions up to 250 000. The intra-assay variation ranges from 1.8 to 15.6% and the inter-assay variation from 9.5 to 27.8%. 18 Plasma CCK concentrations were measured by an RIA, as described previously. 19 The detection limit of the assay is 0.3 pM. The intra-assay variation ranges from 4.6 to 11.5% and the inter-assay variation from 11.3 to 26.1%. 20 
Statistical analysis
Results are expressed as least square means with standard error (s.e.), unless otherwise specified. Satiety and hunger measurements were calculated as absolute ratings. Satiety scores were expressed as percentages of the maximal score (0 mm equaled 0% and 64 mm equaled 100%) and as incremental cumulative areas under the curve (iAUC). The AUC was calculated, using the trapezoid rule, for different periods and corrected for level at the start of that period (incremental AUC). All parameters were analyzed using analysis of variance with participants as blocks and the three treatments as factor. Differences between treatment groups were established using Fisher's least significance difference (two-tailed). A P-value of 0.05 was considered significant. To establish possible relationships between plasma hormones and satiety ratings, Pearson's R correlations between plasma CCK and PYY levels and the corresponding VAS scores for satiety and hunger were calculated. For this correlation, AUC for all time periods and changes in absolute levels in time were used.
Gastrointestinal disturbances were analyzed using frequency of occurrence per time point and a standard ANOVA with the personal scores corrected for each participant's overall mean score.
Statement of ethics
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Results
Satiety scores
As all satiety parameters gave similar-type results, we will only show scores for satiety and hunger. VAS scores for satiety are given in Figure 2 and for hunger in Figure 3 . Fasting scores for hunger and satiety did not differ between the three treatments. Consumption of the meal increased satiety and decreased hunger feelings in all three treatments compared with baseline. At t ¼ 30 min, suppression of hunger levels was significantly more pronounced after the fat-containing compared with the fat-free breakfast, and scores remained lower till the start of the ileal infusion (significant for hunger and satiety at t ¼ 105 min). At t ¼ 150 min, scores for satiety were significantly higher after treatments I3g and I9g compared with C. iAUCs for hunger and satiety for the different time periods are given in Table 1 . From meal ingestion up to the start of the infusion, no significant differences were observed between the different treatments. However, from the start of the infusion till the end of the study day, iAUC for satiety was significantly higher after I3g compared with C.
CCK
Plasma CCK concentrations are given in Figure 4 . Baseline plasma CCK concentrations did not differ between study days. At t ¼ 30 and t ¼ 60 min, plasma CCK concentrations were significantly higher after treatment C compared with I3g and I9g.
The ileal infusions caused a rapid and significant increase in plasma CCK concentrations, resulting in significantly higher plasma concentrations for I9g and for I3g compared with C. With regard to iAUCs (Table 2) , CCK release was significantly larger after C compared with I3g and I9g in the period from meal ingestion till the start of the infusion. iAUCs for I3g and I9g were significantly higher compared with C for the period between the start of the infusion period and the end of the test period. Effect of ileal fat infusion on satiety PWJ Maljaars et al PYY Plasma PYY concentrations are given in Figure 5 . Baseline plasma PYY concentrations did not differ between study days. The fat-containing liquid meal induced a significantly larger postprandial (t ¼ 0-105 min) increase in PYY concentration compared with I3g and I9g ( Table 2 ). The ileal infusion significantly increased plasma PYY concentrations only after treatment I9g, whereas no effect on plasma PYY was seen after treatment I3g. After treatment I9g, plasma PYY remained significantly increased from t ¼ 150-240 min as compared with treatments C and I3g.
Correlations
Plasma hormone levels and the corresponding VAS scores for satiety and hunger were plotted and correlations were calculated between CCK and PYY and satiety scores. For the period starting with the ileal perfusion until noon (105-240 min), significant positive correlations (r ¼ 0.68, Po0.01) were found between the change in plasma CCK secretion and the increase in satiety (Figure 6 ). No significant correlations between PYY concentrations and satiety scores were observed.
Discussion
We are the first to demonstrate in humans that postprandial infusion of a small amount of fat into the ileum reduces hunger and increases satiety. This satiating effect was not different between 3 and 9 g of ileal fat and correlates with CCK secretion. Surprisingly, the release of PYY did not parallel the activation of the ileal brake triggered by ileal fat, as only the high dose (9 g) increased plasma PYY concentrations.
Nutrients administered into the ileum inhibit gastric emptying, 6 slow intestinal motility and transit, 7,21 decrease exocrine pancreatic secretion 9 and reduce food intake. 8 These effects have been attributed to the activation of the ileal brake mechanism. 5 Until recently, it was assumed that undigested nutrients reach the distal small intestine only under conditions of malabsorption or maldigestion. A more recent study in dogs has clearly shown that even under physiological circumstances, unabsorbed fat reaches the distal small intestine and activates the ileal brake mechanism. 22 A function of the ileal brake in the physiological regulation of gastrointestinal motility and secretion has been proposed. 23 The effect of lipids administered into the small intestine on satiety and food intake in humans has been studied previously by Welch et al. 8, 12 These authors demonstrated that infusion of fat in the ileum caused a reduction in food intake in healthy volunteers.
In our experiments, we perfused the ileum with only small amounts of lipid (3 and 9 g of lipid in total, perfused over a 45 min period). This results in delivery of calories to the ileum of 0.6 kcal min À1 and 1.8 kcal min À1 for the 3 and 9 g of oil in total, respectively, both being much lower than the 4.9 kcal min À1 in the studies by Welch et al.
8,12
The 3 g ileal fat resulted in a reduction in appetite and an increase in satiety. This effect was comparable with that induced by the 9 g of ileal fat. Therefore, the satiating effect of ileal fat infusion was not dose dependent. In humans, Pironi et al. 10 were the first to show a significant correlation between the dose of lipids administered to the ileum and the ileal brake effect on gastric emptying. Similarly, Keller et al. 9 demonstrated that the ileal brake induced a dose-dependent inhibition of pancreatic and biliary secretion. No doseresponse studies with regard to the ileal brake and satiety have been performed in humans. With respect to the Effect of ileal fat infusion on satiety PWJ Maljaars et al duodenum, a relation between fat load and satiating effect has been demonstrated previously. 24 It is not apparent why no dose-dependent effects of ileal fat on satiety were observed. Several factors may be involved. First, triacylglycerols need to be hydrolyzed to fatty acids to be able to reduce satiety and food intake. 25 It is well known that the lipolytic capacity in the ileum is smaller compared with the duodenum. 26 A lack of lipase in the ileum may have limited the hydrolysis of the high fat dose. However, as plasma CCK-concentrations increased dose dependently, this is unlikely. Second, after the distal ileal perfusion, fat might directly spill over into the colon, from where no further satiety signals will arise. However, in humans, the satiety response to colonic lipids containing long-chain fatty acids has not been studied in detail. This study shows two important findings regarding gut peptides: (1) CCK, generally considered a 'proximal' gut hormone, was released in a dose-dependent manner during distal small intestinal administration of the oil emulsion, and CCK secretion correlated significantly with changes in satiety; (2) PYY, a distal gut peptide thought to represent activation of the ileal brake, increased after ileal infusion of 9 g of fat, but not after 3 g of fat, and did not correlate with the changes in satiety.
As the dose of ileal oil was increased to 9 g, a significant increase in CCK secretion was observed and correlated significantly with the increase in satiety. We and others have previously reported on the satiating effects of CCK. 13, 19, [27] [28] [29] There is consensus that CCK suppresses food intake on the short term. Our study confirms the correlation between satiety scores and plasma CCK secretion. It is remarkable that secretion of a so-called 'proximal' gut peptide is activated upon ileal delivery of fat. However, Sjolund et al. 30 demonstrated that CCK-producing cells are present in the ileum, confirming observations of Capella et al. 31 The number of CCK-secreting cells in the distal ileum was lower compared with the duodenum or jejunum, but not absent, as in the large intestine. 30 The presence of these I-cells can explain the increase in plasma CCK concentrations observed after infusion of fat in the ileum. To date, release of CCK by ileal fat infusion has previously been shown only by Lin et al. in dogs. 32 In this study by Lin et al., there was no difference in CCK-release between the proximal and distal small intestinal infusions, 32 whereas
Konturek et al. 33 did not find an increase in plasma CCK concentrations. However, in the study by Konturek et al., 33 all intrinsic enteric nerves between the proximal and distal segments were severed, whereas in the Lin study, neural fibers remained intact. Thus, a neural mechanism connecting the distal and proximal small bowel may be responsible for the increase in plasma CCK concentrations after ileal fat infusion. 32 Such a mechanism has been shown in animals for the release of Apolipoprotein A-IV (Apo A-IV), a peptide secreted after intestinal lipid absorption. 34, 35 However, such a neural distal-to-proximal mechanism involved in the secretion of CCK has never been demonstrated in humans. per infusion port. Although covering a larger area of the ileum, this infusion rate may result in a fat load that is below the sensing threshold to induce PYY release. Furthermore, the combination of a small amount of fat with a relatively low lipase activity in the ileum may also have limited the release of PYY after the low dose. Infusion of PYY has been shown to affect eating behavior in various animal models. A recent study by Batterham et al. 36 showed an impressive reduction in food intake after infusion of PYY in both lean and obese human participants. The anorectic effect of PYY has been confirmed by Degen et al. 37 However, in that study, the anorectic effect of exogenous PYY infusion was observed only at pharmacological but not at physiological plasma concentrations. 37 Whereas both 3 and 9 g of ileal fat increased satiety, PYY secretion was increased only during and after the high dose.
Previous studies have suggested that the activation of the ileal brake is accompanied by release of the distal gut hormone PYY. 9, 10, 38 PYY is released from L-endocrine cells of which the high concentrations in humans are found in the distal small intestine, colon and rectum, with progressively more PYY-producing cells when going distally in the gut. The most powerful stimulants for PYY release is fat, especially (triglycerides consisting of) long-chain fatty acids, although amino acids and even carbohydrates have been shown to be effective. Our results do not fully support the hypothesis that PYY is the mediator of the 'ileal brake'. There is evidence that PYY acts as a paracrine agent after release by the L-cell, 39 and this may suggest that plasma levels do not reflect the local effects of PYY. In summary, we have shown that postprandial satiety following a liquid breakfast can be effectively and significantly increased by small amounts (as little as 3 g) of oil perfused into the ileum. This effect correlated with CCK release, but not with PYY release. This satiety effect deserves further evaluation in clinical setting as a factor that may contribute to a reduction in caloric intake and weight loss.
